These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 16778218

  • 1. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C.
    Cancer Res; 2006 Jun 15; 66(12):6395-404. PubMed ID: 16778218
    [Abstract] [Full Text] [Related]

  • 2. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M, Nishigori C, Ichihashi M.
    Exp Dermatol; 2004 Oct 15; 13(10):613-20. PubMed ID: 15447721
    [Abstract] [Full Text] [Related]

  • 3. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O, Dohlsten M, Sjögren HO.
    Cancer Gene Ther; 2000 Oct 15; 7(10):1365-74. PubMed ID: 11059695
    [Abstract] [Full Text] [Related]

  • 4. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 5. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
    Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C, Kim G, Leonard WJ, Hwu P.
    Cancer Res; 2003 Dec 15; 63(24):9016-22. PubMed ID: 14695220
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18.
    Nagai H, Hara I, Horikawa T, Fujii M, Kurimoto M, Kamidono S, Ichihashi M.
    Cancer Invest; 2000 Dec 15; 18(3):206-13. PubMed ID: 10754989
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
    Shimizu K, Fields RC, Redman BG, Giedlin M, Mulé JJ.
    Cancer J Sci Am; 2000 Feb 15; 6 Suppl 1():S67-75. PubMed ID: 10685663
    [Abstract] [Full Text] [Related]

  • 8. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
    Lee CH, Chiang YH, Chang SE, Chong CL, Cheng BM, Roffler SR.
    Clin Cancer Res; 2009 Apr 15; 15(8):2756-66. PubMed ID: 19318495
    [Abstract] [Full Text] [Related]

  • 9. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
    Abdel-Wahab Z, Dar MM, Hester D, Vervaert C, Gangavalli R, Barber J, Darrow TL, Seigler HF.
    Cell Immunol; 1996 Aug 01; 171(2):246-54. PubMed ID: 8806794
    [Abstract] [Full Text] [Related]

  • 10. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL.
    Cancer Res; 1995 Nov 01; 55(21):4980-7. PubMed ID: 7585539
    [Abstract] [Full Text] [Related]

  • 11. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
    Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH, Yamaguchi K.
    Gene Ther; 2000 Dec 01; 7(24):2113-21. PubMed ID: 11223993
    [Abstract] [Full Text] [Related]

  • 12. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
    Lasek W, Golab J, Maśliński W, Switaj T, Bałkowiec EZ, Stokłosa T, Giermasz A, Malejczyk M, Jakóbisiak M.
    Eur Cytokine Netw; 1999 Sep 01; 10(3):345-56. PubMed ID: 10477391
    [Abstract] [Full Text] [Related]

  • 13. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma.
    Marchi LH, Paschoalin T, Travassos LR, Rodrigues EG.
    Cancer Gene Ther; 2011 Feb 01; 18(2):110-22. PubMed ID: 20885448
    [Abstract] [Full Text] [Related]

  • 14. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T, Péron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H.
    J Immunol; 1998 Feb 15; 160(4):1742-9. PubMed ID: 9469432
    [Abstract] [Full Text] [Related]

  • 15. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.
    Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS.
    Cancer Gene Ther; 2002 Nov 15; 9(11):875-83. PubMed ID: 12386826
    [Abstract] [Full Text] [Related]

  • 16. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
    Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG.
    Cancer Res; 1999 Jun 15; 59(12):2802-5. PubMed ID: 10383135
    [Abstract] [Full Text] [Related]

  • 17. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model.
    Cappuccio A, Elishmereni M, Agur Z.
    Cancer Res; 2006 Jul 15; 66(14):7293-300. PubMed ID: 16849579
    [Abstract] [Full Text] [Related]

  • 18. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B.
    Cancer Gene Ther; 2000 Dec 15; 7(12):1543-56. PubMed ID: 11228533
    [Abstract] [Full Text] [Related]

  • 19. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
    Abdel-Wahab Z, Dar M, Osanto S, Fong T, Vervaert CE, Hester D, Jolly D, Seigler HF.
    Cancer Gene Ther; 1997 Dec 15; 4(1):33-41. PubMed ID: 9012449
    [Abstract] [Full Text] [Related]

  • 20. Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate.
    Ito A, Fujioka M, Tanaka K, Kobayashi T, Honda H.
    J Biosci Bioeng; 2005 Jul 15; 100(1):36-42. PubMed ID: 16233848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.